AstraZeneca's Brilinta looks for label boost with trial win, priority review in stroke patients

British drugmaker AstraZeneca has placed a lot of faith—and money—in its wide-ranging R&D program for aging blood thinner Brilinta in hopes of major label expansions. So far, those results have been mixed, but AstraZeneca's drug may be looking at a win in stroke patients.